According to a recent study conducted by Takahashi's team,292 it has been discovered that the topical application of a phosphodiesterase 4 (PDE4) inhibitor effectively enhances AD treatment by suppressing basophil IL‐4 production. The gene discussed is PDE4A; the disease is Alzheimer disease.